Discovering Novel Cancer Treatment Options Using a Comprehensive NGS-based Molecular Testing Panel in the Community Setting ("DINOSAur")
DINOSAur
1 other identifier
observational
572
1 country
1
Brief Summary
To prospectively identify cancer patients whose tumors express specific molecular markers targeted by therapeutic agents from a comprehensive molecular test, for the purpose of selecting the most clinically appropriate treatment in a pragmatic two arm trial.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 21, 2021
CompletedFirst Posted
Study publicly available on registry
January 20, 2023
CompletedStudy Start
First participant enrolled
February 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2025
CompletedMarch 3, 2023
March 1, 2023
9 months
December 21, 2021
March 1, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
European Organization for Research and Treatment of Cancer quality of life Questionnaire-C30 (QLQ-C30)
The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated on an international level and that are available in 110 different language versions.
2 years
Secondary Outcomes (1)
Compare the proportion of patients enrolling in clinical trials
2 years
Study Arms (2)
Active
Newly diagnosed cancer patients.
Control
Historically diagnosed cancer patients.
Interventions
Eligibility Criteria
Newly diagnosed cancer patients at the pathology level.
You may qualify if:
- Patients who have given informed consent in accordance with the methods and procedures of this study
- Diagnosis of cancer (stage 3 and stage 4; solid tumors only) requiring medical care
- Patients who have not received treatment related to his/her cancer
- Patients who are willing to sign a release of medical records to the research team
- Male and female patients ≥18 years of age
- Patients under oncology care of a participating site
- Sufficient clinical status for collection of biospecimen samples within usual care
- Patients who have insurance coverage for CMT
You may not qualify if:
- Patients considered minors in the jurisdiction where the protocol is conducted.
- Patients who are prisoners and pregnant women.
- Patients who cannot provide consent and did not sign a power of attorney.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Adventist Health Glendale
Glendale, California, 91206, United States
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Target Duration
- 2 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
December 21, 2021
First Posted
January 20, 2023
Study Start
February 1, 2023
Primary Completion
November 1, 2023
Study Completion
November 1, 2025
Last Updated
March 3, 2023
Record last verified: 2023-03
Data Sharing
- IPD Sharing
- Will not share